Cargando…
Beinaglutide showed significant weight‐loss benefit and effective glycaemic control for the treatment of type 2 diabetes in a real‐world setting: a 3‐month, multicentre, observational, retrospective, open‐label study
AIMS: The purpose of this study was to examine the effectiveness of beinaglutide on body weight, glycated haemoglobin (HbA(1c)), blood pressure and lipid profiles in patients with type 2 diabetes mellitus (T2DM) in a real‐world setting in China. MATERIALS AND METHODS: This was a multicentre, observa...
Autores principales: | , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6700512/ https://www.ncbi.nlm.nih.gov/pubmed/31452921 http://dx.doi.org/10.1002/osp4.342 |
_version_ | 1783444890320896000 |
---|---|
author | Zhang, Y. L. Zhou, C. Li, X. F. Yang, M. N. Tao, L. Zheng, X. Y. Jia, Y. S. |
author_facet | Zhang, Y. L. Zhou, C. Li, X. F. Yang, M. N. Tao, L. Zheng, X. Y. Jia, Y. S. |
author_sort | Zhang, Y. L. |
collection | PubMed |
description | AIMS: The purpose of this study was to examine the effectiveness of beinaglutide on body weight, glycated haemoglobin (HbA(1c)), blood pressure and lipid profiles in patients with type 2 diabetes mellitus (T2DM) in a real‐world setting in China. MATERIALS AND METHODS: This was a multicentre, observational, retrospective, open‐label study conducted in China. Data were collected from T2DM patients who started treatment with beinaglutide between 2017 and 2018. RESULTS: A total of 314 patients were included in the study. After 3 months of treatment with beinaglutide, there were significant reductions in body weight (−10.05 kg [95% confidence interval −9.29 to −10.80]), HbA(1c) (−2.87% [−2.62 to −3.11]), 2‐h postprandial plasma glucose (−5.46 mmol L(−1) [−4.96 to −5.95]) and fasting plasma glucose (−3.04 mmol L(−1) [−2.78 to −3.31]) (all p < 0.0001). In addition, 84.96% and 72.18% of the patients achieved weight loss of ≥5% and ≥10%, respectively. Subgroup analyses showed that weight loss was significantly greater in patients with ≥28 kg m(−2) of baseline body mass index and 0.60 mg of beinaglutide doses (p = 0.007 and p < 0.0001, respectively). HbA(1c) reductions were significantly greater in patients with ≥9.0% baseline HbA(1c) and in those administered 0.40–0.48 mg of beinaglutide doses (all p < 0.0001). Weight loss at 3 months was positively correlated with baseline BMI and the dose of beinaglutide. Positive determinants for HbA(1c) reduction after 3 months were baseline HbA(1c) and the dose of beinaglutide. CONCLUSIONS: These observational results confirmed the benefits of beinaglutide in weight loss and glycaemic control and support the use of beinaglutide as an effective treatment for T2DM. |
format | Online Article Text |
id | pubmed-6700512 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2019 |
publisher | John Wiley and Sons Inc. |
record_format | MEDLINE/PubMed |
spelling | pubmed-67005122019-08-26 Beinaglutide showed significant weight‐loss benefit and effective glycaemic control for the treatment of type 2 diabetes in a real‐world setting: a 3‐month, multicentre, observational, retrospective, open‐label study Zhang, Y. L. Zhou, C. Li, X. F. Yang, M. N. Tao, L. Zheng, X. Y. Jia, Y. S. Obes Sci Pract Original Articles AIMS: The purpose of this study was to examine the effectiveness of beinaglutide on body weight, glycated haemoglobin (HbA(1c)), blood pressure and lipid profiles in patients with type 2 diabetes mellitus (T2DM) in a real‐world setting in China. MATERIALS AND METHODS: This was a multicentre, observational, retrospective, open‐label study conducted in China. Data were collected from T2DM patients who started treatment with beinaglutide between 2017 and 2018. RESULTS: A total of 314 patients were included in the study. After 3 months of treatment with beinaglutide, there were significant reductions in body weight (−10.05 kg [95% confidence interval −9.29 to −10.80]), HbA(1c) (−2.87% [−2.62 to −3.11]), 2‐h postprandial plasma glucose (−5.46 mmol L(−1) [−4.96 to −5.95]) and fasting plasma glucose (−3.04 mmol L(−1) [−2.78 to −3.31]) (all p < 0.0001). In addition, 84.96% and 72.18% of the patients achieved weight loss of ≥5% and ≥10%, respectively. Subgroup analyses showed that weight loss was significantly greater in patients with ≥28 kg m(−2) of baseline body mass index and 0.60 mg of beinaglutide doses (p = 0.007 and p < 0.0001, respectively). HbA(1c) reductions were significantly greater in patients with ≥9.0% baseline HbA(1c) and in those administered 0.40–0.48 mg of beinaglutide doses (all p < 0.0001). Weight loss at 3 months was positively correlated with baseline BMI and the dose of beinaglutide. Positive determinants for HbA(1c) reduction after 3 months were baseline HbA(1c) and the dose of beinaglutide. CONCLUSIONS: These observational results confirmed the benefits of beinaglutide in weight loss and glycaemic control and support the use of beinaglutide as an effective treatment for T2DM. John Wiley and Sons Inc. 2019-06-17 /pmc/articles/PMC6700512/ /pubmed/31452921 http://dx.doi.org/10.1002/osp4.342 Text en © 2019 The Authors Obesity Science & Practice published by John Wiley & Sons Ltd, World Obesity and The Obesity Society. This is an open access article under the terms of the http://creativecommons.org/licenses/by/4.0/ License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Original Articles Zhang, Y. L. Zhou, C. Li, X. F. Yang, M. N. Tao, L. Zheng, X. Y. Jia, Y. S. Beinaglutide showed significant weight‐loss benefit and effective glycaemic control for the treatment of type 2 diabetes in a real‐world setting: a 3‐month, multicentre, observational, retrospective, open‐label study |
title | Beinaglutide showed significant weight‐loss benefit and effective glycaemic control for the treatment of type 2 diabetes in a real‐world setting: a 3‐month, multicentre, observational, retrospective, open‐label study |
title_full | Beinaglutide showed significant weight‐loss benefit and effective glycaemic control for the treatment of type 2 diabetes in a real‐world setting: a 3‐month, multicentre, observational, retrospective, open‐label study |
title_fullStr | Beinaglutide showed significant weight‐loss benefit and effective glycaemic control for the treatment of type 2 diabetes in a real‐world setting: a 3‐month, multicentre, observational, retrospective, open‐label study |
title_full_unstemmed | Beinaglutide showed significant weight‐loss benefit and effective glycaemic control for the treatment of type 2 diabetes in a real‐world setting: a 3‐month, multicentre, observational, retrospective, open‐label study |
title_short | Beinaglutide showed significant weight‐loss benefit and effective glycaemic control for the treatment of type 2 diabetes in a real‐world setting: a 3‐month, multicentre, observational, retrospective, open‐label study |
title_sort | beinaglutide showed significant weight‐loss benefit and effective glycaemic control for the treatment of type 2 diabetes in a real‐world setting: a 3‐month, multicentre, observational, retrospective, open‐label study |
topic | Original Articles |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6700512/ https://www.ncbi.nlm.nih.gov/pubmed/31452921 http://dx.doi.org/10.1002/osp4.342 |
work_keys_str_mv | AT zhangyl beinaglutideshowedsignificantweightlossbenefitandeffectiveglycaemiccontrolforthetreatmentoftype2diabetesinarealworldsettinga3monthmulticentreobservationalretrospectiveopenlabelstudy AT zhouc beinaglutideshowedsignificantweightlossbenefitandeffectiveglycaemiccontrolforthetreatmentoftype2diabetesinarealworldsettinga3monthmulticentreobservationalretrospectiveopenlabelstudy AT lixf beinaglutideshowedsignificantweightlossbenefitandeffectiveglycaemiccontrolforthetreatmentoftype2diabetesinarealworldsettinga3monthmulticentreobservationalretrospectiveopenlabelstudy AT yangmn beinaglutideshowedsignificantweightlossbenefitandeffectiveglycaemiccontrolforthetreatmentoftype2diabetesinarealworldsettinga3monthmulticentreobservationalretrospectiveopenlabelstudy AT taol beinaglutideshowedsignificantweightlossbenefitandeffectiveglycaemiccontrolforthetreatmentoftype2diabetesinarealworldsettinga3monthmulticentreobservationalretrospectiveopenlabelstudy AT zhengxy beinaglutideshowedsignificantweightlossbenefitandeffectiveglycaemiccontrolforthetreatmentoftype2diabetesinarealworldsettinga3monthmulticentreobservationalretrospectiveopenlabelstudy AT jiays beinaglutideshowedsignificantweightlossbenefitandeffectiveglycaemiccontrolforthetreatmentoftype2diabetesinarealworldsettinga3monthmulticentreobservationalretrospectiveopenlabelstudy |